MedPath

Assessment of the efficacy and safety of combination therapy of fluconazole 1% and urea 40% comparing with fluconazole 1% alone in the treatment of onychomycosis

Phase 3
Conditions
onychomycosis.
Onychomycosis
Registration Number
IRCT138705301059N1
Lead Sponsor
Pasteur Institute of Iran
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
70
Inclusion Criteria

Presence of at least 25% involvement of the target nail, at least 2 mm of healthy nail from the nail fold to the proximal Dermatophyte onychomycosis border. Exclusion criteria: Non-dermatophytic onychomycosis, hypersensitivity to Azole derivatives, unwilling to sign informed consent, receiving systemic anti-fungal treatment or any investigational drug during three month prior to study

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Onychomycosis treatment. Timepoint: One month before intervention,and at months 2, 4, and 6 after intervention. Method of measurement: Laboratory Examination.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath